Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
Accentia Biopharmaceuticals Reports Fiscal Third Quarter 2007 Financial Results
August 31st, 2007
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) has released the financial results for its fiscal 2007 third quarter, ended June 30, 2007. During the third quarter of fiscal 2007, the Company's primary focus was on product development of its three late-stage potential blockbuster therapeutics: SinuNase(TM) for Chronic Sinusitis (CS), Revimmune for refractory multiple sclerosis, and BiovaxID for non-Hodgkin's lymphoma. Accentia has two business segments: a specialty pharmaceuticals division, which markets products with a special emphasis on specialists who treat severe chronic sinusitis, and a biopharmaceutical consulting and product development...
Source: Drug Week (2007-08-31)
|
